Allurion Technologies, Inc. ("Allurion" or the "Company") , a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the "Special Meeting"), originally ...

This sets up well for a randomized trial anticipated later this year, which could potentially set up Allurion’s gastric balloon in combination with GLP-1’s as the new standard of care for ...

Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated with GLP1 therapy, which the analyst calls ...

Shares of Ouster, Inc. OUST rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Ouster reported quarterly losses of 48 ...

The Allurion Program includes a swallowable gastric balloon, which is part of a broader weight-loss platform that also features virtual care and a behavior change program. With revenue of $34.75 ...

Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on weight loss associated with its gastric balloon in combination with Novo ...

or distribution of balloons in the state altogether. Other states with similar measures include Delaware, Tennessee, Virginia, California, Hawaii and Maryland. The New Hampshire bill will next ...